Références Scientifiques Consultez la littérature scientifique qui soutient nos cibles moléculaires et notre approche létale synthétique. janvier 2020 CRISPR/CAS9-based DNA damage response screens reveal gene-drug interactions Su D, Feng X, Colic M, et al. ScienceDirect novembre 2019 Synthetic lethality as an engine for cancer drug target discovery Huang A, Garraway LA, Ashworth A, Weber B Nature Reviews Drug Discover juin 2019 A CRISPR Way to Identify Cancer Targets Hahn WC New England Journal of Medicine mai 2019 First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors De Bono JS, Shao DP, Caldwell R, et al. Journal of Clinical Oncology avril 2018 Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas Knijenburg TA, Wang LH, Zimmermann MT, et al. Cell Reports mai 2017 Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients Zehir A, Benayed R, Shah RH, et al. Nature septembre 2016 Synthetic lethality in lung cancer and translation to clinical therapies Leung AW, de Silva T, Bally MB, Lockwood WW Molecular Cancer novembre 2015 High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities Hart T, Chandrashekhar M, Aregger M, et al. Cell août 2005 The concept of synthetic lethality in the context of anticancer therapy Kaelin WG Jr. Nature février 2004 Global mapping of the yeast genetic interaction network Tong AH, Lesage G, Bader GD, et al. Science 1234 Notre pipeline comprend plusieurs programmes de développement. Voir Notre Pipeline
